Your Apple Watch might just be shorn off one of its key features: the blood oxygen level display. A US court on Thursday (Jan 17) upheld a ban on the sale of Apple watches, allegedly infringing on a patent related to this medical technology. 
 
The dispute involves a smaller company which claims to have introduced the feature.

Blood oxygen level&nbsp;is a key feature used by those wearing Apple Watches, particularly fitness enthusiasts, and is very useful in medical situations. 
 
On the other side&nbsp;of the patent dispute is Masimo,&nbsp;a health technology and consumer electronics company based in Irvine, California. 
 
The Cupertino, California-based giant was earlier allowed to sell Series 9 and Ultra 2&nbsp;as the patent case was continuing.

WATCH:&nbsp;Apple overtakes Samsung as world's biggest seller of smartphones

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/apple-overtakes-samsung-as-worlds-biggest-seller-of-smartphones-681040/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

 
 
However, as per the court ruling, the models facing the dispute cannot be imported from 5:00 PM local time on Thursday. 
&nbsp;

<h2>Apple reacts to court ruling on smartwatch</h2>

On Thursday, Apple, which "strongly disagreed" that it violated patents, hinted it might disable the oximeter feature.

"Pending the appeal, Apple is taking steps to comply with the ruling while ensuring customers have access to Apple Watch with limited disruption," it said in a release.

 
Masimo,&nbsp;a health technology and consumer electronics company based in Irvine, California, reacted to the ruling in a press release, with its CEO sharing on X that the ruling was a "victory for American innovation".

&nbsp;

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Today marks a victory for American Innovation and hospital-grade wearables consumers can trust. <a href="https://twitter.com/hashtag/PressRelease?src=hash&amp;ref_src=twsrc%5Etfw">#PressRelease</a> <a href="https://t.co/1LlQi0Cw3I">https://t.co/1LlQi0Cw3I</a> <a href="https://t.co/h2jnxtJu1H">pic.twitter.com/h2jnxtJu1H</a>
— Joe Kiani (@JoeKiani) <a href="https://twitter.com/JoeKiani/status/1747834852492169362?ref_src=twsrc%5Etfw">January 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

“The Federal Circuit's decision to lift the temporary stay is a victory for the integrity of the American patent system and the safety of people relying on pulse oximetry,” a Masimo release quoted Kiani as saying. 
&nbsp;

“It affirms that even the largest and most powerful companies must respect the intellectual rights of American inventors and must deal with the consequences when they are caught infringing others’ patents.”

Also read:&nbsp;<a href="https://www.wionews.com/technology/biden-administration-allows-apple-watch-import-ban-in-us-following-tribunal-ruling-673768">Biden administration allows Apple Watch import ban in US following tribunal ruling</a>

<h2>Masimo's allegations against Apple on patent infringement</h2>

Masimo claimed in its release that the company had&nbsp;earlier made available a study showing that Apple Watch’s pulse oximetry missed over 90 per cent&nbsp;of potentially life-threatening events.

"The Apple Watch pulse oximeter was not cleared by the United States Food and Drug Administration for medical use," Masimo claimed in the release&nbsp;while adding that&nbsp;the Masimo W1 health watch "was recently cleared by the FDA for its indicated medical uses, including continuous pulse oximetry".

also read:&nbsp;<a href="https://www.wionews.com/technology/apple-begins-disbursing-batterygate-settlement-payments-to-us-iphone-users-report-677832">Apple begins disbursing ‘batterygate’ settlement payments to US iPhone users: Report</a>

Masimo said in its release that its pulse oximetry technology "is used on over 200 million patients in hospitals a year".

According to the company, the feature helped save babies’ eyesight in the neonatal ICU, detect critical congenital heart defects in newborns and save the lives of patients in post-surgical wards who are taking opioids.

Masimo and sister company Cercacor claimed that Apple poached its key staff, and accused the tech giant of stealing its blood oxygen level detection technology.

The US trade commission agreed to some of these claims last&nbsp;October and banned imports and sales of some of the Apple Watch models. But this ban was halted as hearings were going on Apple's appeal.

Most versions of Apple's watches, including the Series 9 and Ultra 2, have included the feature since 2020, BBC said in a report, adding some models do not have the feature.

(With inputs from agencies) 
&nbsp;

&nbsp;

Your Apple Watch might just be shorn off one of its key features: the blood oxygen level display. A US court on Thursday (Jan 17) upheld a ban on the sale of Apple watches, allegedly infringing on a patent related to this medical technology.

Your Apple Watch might just be shorn off one of its key features: the blood oxygen level display. A US court on Thursday (Jan 17) upheld a ban on the sale of Apple watches, allegedly infringing on a patent related to this medical technology. The dispute involves a smaller company which claims to have introduced the feature. Blood oxygen level is a key feature used by those wearing Apple Watches, particularly fitness enthusiasts, and is very useful in medical situations. On the other side of the patent dispute is Masimo, a health technology and consumer electronics company based in Irvine, California. The Cupertino, California-based giant was earlier allowed to sell Series 9 and Ultra 2 as the patent case was continuing. WATCH: Apple overtakes Samsung as world's biggest seller of smartphones × However, as per the court ruling, the models facing the dispute cannot be imported from 5:00 PM local time on Thursday. Apple reacts to court ruling on smartwatch On Thursday, Apple, which "strongly disagreed" that it violated patents, hinted it might disable the oximeter feature. "Pending the appeal, Apple is taking steps to comply with the ruling while ensuring customers have access to Apple Watch with limited disruption," it said in a release. Masimo, a health technology and consumer electronics company based in Irvine, California, reacted to the ruling in a press release, with its CEO sharing on X that the ruling was a "victory for American innovation". Today marks a victory for American Innovation and hospital-grade wearables consumers can trust. #PressRelease https://t.co/1LlQi0Cw3I pic.twitter.com/h2jnxtJu1H — Joe Kiani (@JoeKiani) January 18, 2024 × “The Federal Circuit's decision to lift the temporary stay is a victory for the integrity of the American patent system and the safety of people relying on pulse oximetry,” a Masimo release quoted Kiani as saying. “It affirms that even the largest and most powerful companies must respect the intellectual rights of American inventors and must deal with the consequences when they are caught infringing others’ patents.” Also read: Biden administration allows Apple Watch import ban in US following tribunal ruling Masimo's allegations against Apple on patent infringement Masimo claimed in its release that the company had earlier made available a study showing that Apple Watch’s pulse oximetry missed over 90 per cent of potentially life-threatening events. "The Apple Watch pulse oximeter was not cleared by the United States Food and Drug Administration for medical use," Masimo claimed in the release while adding that the Masimo W1 health watch "was recently cleared by the FDA for its indicated medical uses, including continuous pulse oximetry". also read: Apple begins disbursing ‘batterygate’ settlement payments to US iPhone users: Report Masimo said in its release that its pulse oximetry technology "is used on over 200 million patients in hospitals a year". According to the company, the feature helped save babies’ eyesight in the neonatal ICU, detect critical congenital heart defects in newborns and save the lives of patients in post-surgical wards who are taking opioids. Masimo and sister company Cercacor claimed that Apple poached its key staff, and accused the tech giant of stealing its blood oxygen level detection technology. The US trade commission agreed to some of these claims last October and banned imports and sales of some of the Apple Watch models. But this ban was halted as hearings were going on Apple's appeal. Most versions of Apple's watches, including the Series 9 and Ultra 2, have included the feature since 2020, BBC said in a report, adding some models do not have the feature. (With inputs from agencies)

Apple watch patent row: As US upholds ban on sale, tech giant might disable oxygen display in some devices

Your Apple Watch might just be shorn off one of its key features: the blood oxygen level display. A US court on Thursday (Jan 17) upheld a ban on the sale of Apple watches, allegedly infringing on a patent related to this medical technology. 
 
The dispute involves a smaller company which claims to have introduced the feature.

Blood oxygen levels is a key feature used by those wearing Apple Watches, particularly fitness enthusiasts, and is very useful in medical situations. 
 
On the other side&nbsp;of the patent dispute is Masimo,&nbsp;a health technology and consumer electronics company based in Irvine, California. 
 
The Cupertino, California-based giant was earlier allowed to sell Series 9 and Ultra 2&nbsp; as the patent case was continuing.

WATCH:&nbsp;Apple overtakes Samsung as world's biggest seller of smartphones

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/apple-overtakes-samsung-as-worlds-biggest-seller-of-smartphones-681040/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

 
 
As per the court ruling, the models facing the dispute cannot be imported from 17:00 PM local time on Thursday. 
 
 
On Thursday, Apple said it will release watches without the disputed blood oxygen feature to keep them on shelves.

 
Masimo reacted to the ruling in a press release, with its CEO sharing on X that the ruling was a "victory for American innovation."

&nbsp;

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Today marks a victory for American Innovation and hospital-grade wearables consumers can trust. <a href="https://twitter.com/hashtag/PressRelease?src=hash&amp;ref_src=twsrc%5Etfw">#PressRelease</a> <a href="https://t.co/1LlQi0Cw3I">https://t.co/1LlQi0Cw3I</a> <a href="https://t.co/h2jnxtJu1H">pic.twitter.com/h2jnxtJu1H</a>
— Joe Kiani (@JoeKiani) <a href="https://twitter.com/JoeKiani/status/1747834852492169362?ref_src=twsrc%5Etfw">January 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

“the Federal Circuit's decision to lift the temporary stay is a victory for the integrity of the American patent system and the safety of people relying on pulse oximetry,” said Joe Kiani, Founder and CEO of Masimo.

“It affirms that even the largest and most powerful companies must respect the intellectual rights of American inventors and must deal with the consequences when they are caught infringing others’ patents.”

Also read:&nbsp;<a href="https://www.wionews.com/technology/biden-administration-allows-apple-watch-import-ban-in-us-following-tribunal-ruling-673768">Biden administration allows Apple Watch import ban in US following tribunal ruling</a>

Masimo said in its release that the company had&nbsp;earlier made available a study showing that Apple Watch’s pulse oximetry missed over 90% of potentially life-threatening events.

"The Apple Watch pulse oximeter was not cleared by the United Stated Food and Drug Administration for medical use," Masimo claimed in the release while claiming that&nbsp;the Masimo W1 health watch was recently cleared by the FDA for its indicated medical uses, including continuous pulse oximetry.

also read:&nbsp;<a href="https://www.wionews.com/technology/apple-begins-disbursing-batterygate-settlement-payments-to-us-iphone-users-report-677832">Apple begins disbursing ‘batterygate’ settlement payments to US iPhone users: Report</a>

Masimo said in its release that its pulse oximetry technology "is used on over 200 million patients in hospitals a year."

&nbsp;

According to the company, the feature helped save babies’ eyesight in the neonatal ICU, detect critical congenital heart defects in newborns, and save the lives of patients in post-surgical wards who are taking opioids.

 
Masimo and sister company Cercacor claimed that Apple poached its key staff, and accused the tech giant of stealing its blood oxygen level detection technology.

The US trade commission had agreed to some of this claims last&nbsp;October and banned imports and sales of some of the Apple Watch models. But this ban was halted as hearings were going on Apple's appeal.

&nbsp;

Most versions of Apple's watches, including the Series 9 and Ultra 2, have included the feature since 2020, BBC said in a report, adding some models do not have the feature.

&nbsp;

(With inputs from agencies) 
&nbsp;

&nbsp;

Your Apple Watch might just be shorn off one of its key features: the blood oxygen level display. A US court on Thursday (Jan 17) upheld a ban on the sale of Apple watches, allegedly infringing on a patent related to this medical technology. The dispute involves a smaller company which claims to have introduced the feature. Blood oxygen levels is a key feature used by those wearing Apple Watches, particularly fitness enthusiasts, and is very useful in medical situations. On the other side of the patent dispute is Masimo, a health technology and consumer electronics company based in Irvine, California. The Cupertino, California-based giant was earlier allowed to sell Series 9 and Ultra 2 as the patent case was continuing. WATCH: Apple overtakes Samsung as world's biggest seller of smartphones × As per the court ruling, the models facing the dispute cannot be imported from 17:00 PM local time on Thursday. On Thursday, Apple said it will release watches without the disputed blood oxygen feature to keep them on shelves. Masimo reacted to the ruling in a press release, with its CEO sharing on X that the ruling was a "victory for American innovation." Today marks a victory for American Innovation and hospital-grade wearables consumers can trust. #PressRelease https://t.co/1LlQi0Cw3I pic.twitter.com/h2jnxtJu1H — Joe Kiani (@JoeKiani) January 18, 2024 × “the Federal Circuit's decision to lift the temporary stay is a victory for the integrity of the American patent system and the safety of people relying on pulse oximetry,” said Joe Kiani, Founder and CEO of Masimo. “It affirms that even the largest and most powerful companies must respect the intellectual rights of American inventors and must deal with the consequences when they are caught infringing others’ patents.” Also read: Biden administration allows Apple Watch import ban in US following tribunal ruling Masimo said in its release that the company had earlier made available a study showing that Apple Watch’s pulse oximetry missed over 90% of potentially life-threatening events. "The Apple Watch pulse oximeter was not cleared by the United Stated Food and Drug Administration for medical use," Masimo claimed in the release while claiming that the Masimo W1 health watch was recently cleared by the FDA for its indicated medical uses, including continuous pulse oximetry. also read: Apple begins disbursing ‘batterygate’ settlement payments to US iPhone users: Report Masimo said in its release that its pulse oximetry technology "is used on over 200 million patients in hospitals a year." According to the company, the feature helped save babies’ eyesight in the neonatal ICU, detect critical congenital heart defects in newborns, and save the lives of patients in post-surgical wards who are taking opioids. Masimo and sister company Cercacor claimed that Apple poached its key staff, and accused the tech giant of stealing its blood oxygen level detection technology. The US trade commission had agreed to some of this claims last October and banned imports and sales of some of the Apple Watch models. But this ban was halted as hearings were going on Apple's appeal. Most versions of Apple's watches, including the Series 9 and Ultra 2, have included the feature since 2020, BBC said in a report, adding some models do not have the feature. (With inputs from agencies)

Apple watch patent row: As US upholds ban on sale, tech giant might disable this feature in iWatch

Apple Inc's plea to avoid paying $440 million in damages to VirnetX Inc for using the patent licensing firm's security technology without permission in features such as FaceTime video calling was denied by the US Supreme Court.

Apple Inc's plea to avoid paying $440 million in damages to VirnetX Inc for using the patent licensing firm's security technology without permission in features such as FaceTime video calling was denied by the US Supreme Court. Apple's appeal was rejected by the judges in this case which spans a decade, wherein a Texas jury had discovered in 2016 that the iPhone manufacturer had infringed VirnetX's patents, following which the patent licensing firm was awarded $302 million. The amount was increased to $439.7 million including interest and other costs. Also Read: US jury asks Apple to pay $145 million in damages to Canada's WiLan In 2010, the Nevada-based VirnetX filed a lawsuit against California-based Apple of infringing four patents for secure networks, known as virtual private networks, and secure communications links. VirnetX was adamant that Apple infringed with its FaceTime and VPN on Demand features in products such as the iPhone and iPad. The judgement against apple was upheld last year by the US Court of Appeals for the Federal Circuit in Washington. During the hearings, Apple and other tech titans requested a review of the validity of VirnetX patents by a tribunal of the US Patent and Trademark Office. Also Read: Samsung to pay $539 million to Apple for copying patented smartphone designs, features Key parts of the patents at issue, in this case, were cancelled by the Tribunal but in separate decisions issued last year, the Federal Circuit set aside certain of the tribunal's rulings which brought VirnetX closer to collecting damages from Apple. The world-renowned mobile phone manufacturer appealed to the Supreme Court, arguing that the damages should be recalculated because the specific patents VirnetX accused it of infringing with FaceTime were nearly wiped out. Also Read: Top US court rejects Samsung's appeal on patent loss to Apple In a court filing, Apple called the Federal Circuit's opposition to indulge its demands "legally wrong and grossly unfair." The company also stated that lower courts unlawfully granted requests from VirnetX and granted them compensation for damages far beyond the value of the patented invention. VirnetX issued a statement saying that "The entire damages award ... remains supported by claims that a jury - and the Federal Circuit - found valid years ago and that have not been cancelled since."

Apple appeals rejected by US Supreme Court in legal battle with VirnetX

Apple has settled a patent dispute with Finnish telecom equipment maker Nokia and agreed to buy more of its network products and services, sending Nokia shares up 7 per cent.

The deal means Nokia will get bigger royalties from Apple for using its mobile phone patents, helping offset the impact of waning demand for its mobile network hardware.

Such legal battles are common in the industry but can drag on for years and analysts had not been expecting such a quick resolution to the dispute that started in December.

Under the deal announced in a joint statement from the companies on Tuesday, Nokia will also supply network infrastructure products to Apple, and Apple will resume sales of Nokia&#39;s digital health products in retail and online stores and look at further collaboration in health.

Digital health is one of the areas Nokia is targeting as it tries to develop new businesses to offset the industry-wide slump in demand for network equipment. Last year, Nokia bought France&#39;s Withings S.A., a small firm with products such as activity trackers and baby monitors built on digital platforms.

&quot;There could emerge big future value from this as Apple could become an important distribution channel,&quot; said Handelsbanken analyst Daniel Djurberg, who has an &quot;accumulate&quot; recommendation for Nokia shares.

&quot;I have not given any value so far for Nokia&#39;s digital health business, but might apply an option value to it.&quot;

Indutrial deal

Nokia Chief Executive Rajeev Suri told the company&#39;s annual general meeting later on Tuesday that the deal would help expand network sales beyond telecom operators to global internet and technology giants.

&quot;(The deal) involves a business collaboration ... in particular in areas of IP and optical equipment, which is quite key to webscale players when they build their data centers,&quot; he said. &quot;It&#39;s a good deal, a multi-year licensing deal, and I love it that it has an industrial deal and aspect to it.&quot;

Under the patent license agreement, Nokia will receive a &quot;significant&quot; upfront cash payment and additional revenues from Apple starting from the current quarter. The companies did not give further details but analysts said the revenue was likely to be far higher than a previous deal.

Inge Heydorn, fund manager at Sentat Asset Management, said it was a smart move to collaborate on digital health products.

&quot;It&#39;s interesting for Nokia in a 5&nbsp;to 10&nbsp;year perspective since I think it will be hard to be profitable within mobile infrastructure,&quot; said Heydorn, whose firm does not hold any shares in Nokia.

Nokia shares, which fell in December when the patent dispute was announced, jumped to their highest since February 2016 and were up 6.7 per cent at 5.89 euros&nbsp;by 1509 GMT.

A previous patent license contract between the companies expired last year, and both sides took legal action in December. Apple complained of being overcharged and Nokia responded by accusing Apple of violating technology patents.

In the absence of a new deal, Nokia cut its annual run-rate forecast in December for patent and brand licensing sales to 800 million euros ($900 million) from 950 million euros ($1000 million) previously. In its latest quarterly report released in April, Nokia stopped giving an annual run-rate forecast altogether.

&quot;(The agreement) moves our relationship with Apple from being adversaries in court to business partners,&quot; Nokia&#39;s Chief Legal Officer Maria Varsellona said in a statement.

Quick resolution

Analysts were surprised by the relatively quick resolution of the dispute between Apple and Nokia.

&quot;Nokia told analysts in April don&#39;t calculate on any license revenue from Apple, not even in 2018, so this is a positive surprise. It will also limit Nokia&#39;s legal expenses,&quot; said Djurberg who said he would probably raise his Nokia estimates.

&quot;For Nokia, it&#39;s good news they got this out of the way, but we still have to wait for details about the financial impact,&quot; said OP Equities analyst Hannu Rauhala.

&quot;The previous annual rate was 150 million euros ($167 million), so I assume this to be more, around 500 million euros ($558 million).&quot;

Rauhala said Apple might have been willing to settle with Nokia as the US&nbsp;company&#39;s patent battle with chipmaker Qualcomm has escalated.

Patent royalties represent only a sliver of Nokia&#39;s overall revenue, more than 90 per cent of which comes from telecom&nbsp;network equipment. But licensing payments are highly profitable and the network business is suffering an industry-wide slump.

Nokia&#39;s patents cover technology that reduces the need for hardware components in a phone, conserves battery life, increases radio reception, helps in recovering lost phones and enables voice recognition, among other features.

Once the world&#39;s dominant cellphone maker, Nokia sold its handset business to Microsoft in 2014 to focus on its network business and large portfolio of mobile device patents.

Nokia&#39;s total sales in 2016 were about 24 billion euros ($27 billion).

(Reuters)

Nokia will get bigger royalties from Apple for using its mobile phone patents

Apple has settled a patent dispute with Finnish telecom equipment maker Nokia and agreed to buy more of its network products and services, sending Nokia shares up 7 per cent. The deal means Nokia will get bigger royalties from Apple for using its mobile phone patents, helping offset the impact of waning demand for its mobile network hardware. Such legal battles are common in the industry but can drag on for years and analysts had not been expecting such a quick resolution to the dispute that started in December. Under the deal announced in a joint statement from the companies on Tuesday, Nokia will also supply network infrastructure products to Apple, and Apple will resume sales of Nokia's digital health products in retail and online stores and look at further collaboration in health. Digital health is one of the areas Nokia is targeting as it tries to develop new businesses to offset the industry-wide slump in demand for network equipment. Last year, Nokia bought France's Withings S.A., a small firm with products such as activity trackers and baby monitors built on digital platforms. "There could emerge big future value from this as Apple could become an important distribution channel," said Handelsbanken analyst Daniel Djurberg, who has an "accumulate" recommendation for Nokia shares. "I have not given any value so far for Nokia's digital health business, but might apply an option value to it." Indutrial deal Nokia Chief Executive Rajeev Suri told the company's annual general meeting later on Tuesday that the deal would help expand network sales beyond telecom operators to global internet and technology giants. "(The deal) involves a business collaboration ... in particular in areas of IP and optical equipment, which is quite key to webscale players when they build their data centers," he said. "It's a good deal, a multi-year licensing deal, and I love it that it has an industrial deal and aspect to it." Under the patent license agreement, Nokia will receive a "significant" upfront cash payment and additional revenues from Apple starting from the current quarter. The companies did not give further details but analysts said the revenue was likely to be far higher than a previous deal. Inge Heydorn, fund manager at Sentat Asset Management, said it was a smart move to collaborate on digital health products. "It's interesting for Nokia in a 5 to 10 year perspective since I think it will be hard to be profitable within mobile infrastructure," said Heydorn, whose firm does not hold any shares in Nokia. Nokia shares, which fell in December when the patent dispute was announced, jumped to their highest since February 2016 and were up 6.7 per cent at 5.89 euros by 1509 GMT. A previous patent license contract between the companies expired last year, and both sides took legal action in December. Apple complained of being overcharged and Nokia responded by accusing Apple of violating technology patents. In the absence of a new deal, Nokia cut its annual run-rate forecast in December for patent and brand licensing sales to 800 million euros ($900 million) from 950 million euros ($1000 million) previously. In its latest quarterly report released in April, Nokia stopped giving an annual run-rate forecast altogether. "(The agreement) moves our relationship with Apple from being adversaries in court to business partners," Nokia's Chief Legal Officer Maria Varsellona said in a statement. Quick resolution Analysts were surprised by the relatively quick resolution of the dispute between Apple and Nokia. "Nokia told analysts in April don't calculate on any license revenue from Apple, not even in 2018, so this is a positive surprise. It will also limit Nokia's legal expenses," said Djurberg who said he would probably raise his Nokia estimates. "For Nokia, it's good news they got this out of the way, but we still have to wait for details about the financial impact," said OP Equities analyst Hannu Rauhala. "The previous annual rate was 150 million euros ($167 million), so I assume this to be more, around 500 million euros ($558 million)." Rauhala said Apple might have been willing to settle with Nokia as the US company's patent battle with chipmaker Qualcomm has escalated. Patent royalties represent only a sliver of Nokia's overall revenue, more than 90 per cent of which comes from telecom network equipment. But licensing payments are highly profitable and the network business is suffering an industry-wide slump. Nokia's patents cover technology that reduces the need for hardware components in a phone, conserves battery life, increases radio reception, helps in recovering lost phones and enables voice recognition, among other features. Once the world's dominant cellphone maker, Nokia sold its handset business to Microsoft in 2014 to focus on its network business and large portfolio of mobile device patents. Nokia's total sales in 2016 were about 24 billion euros ($27 billion). (Reuters)

Nokia and Apple see deeper partnership after ending patent dispute

patent-dispute

Patent Dispute, News on Patent Dispute, stories on Patent Dispute, articles on Patent Dispute, Patent Dispute stories at Wion, Patent Dispute news, Patent Dispute latest news